AbbVie sees negative Q3, full-year impact from IPR&D and milestones expense Posted on October 3, 2025 by wpadmin AbbVie (NYSE:ABBV) said it will incur a negative impact of $1.50 to GAAP and non-GAAP diluted earnings per share in Q3 due to acquired IPR&D and milestones expense of $2.7B. As a result, the company now sees Q3 adjusted diluted
